Back to Results
First PageMeta Content
Finance / Reverse convertible securities / UBS / Bond / Structured product / Banking in Switzerland / Specialized investment fund / Credit rating agency / Exchange-traded note / Financial economics / Investment / Economics


12.00% p.a. CHF Kick-In GOAL Linked to worst of Basilea / Gilead / Vertex Pharmaceuticals Issued by UBS AG, London Branch Cash settled; Quanto Style SVSP/EUSIPA Product Type: Barrier Reverse Convertible[removed]Valor: 272
Add to Reading List

Document Date: 2015-03-13 10:25:33

Open Document

File Size: 233,98 KB

Share Result on Facebook

City

Zurich / Basel / /

Company

London Branch UBS AG / GILEAD SCIENCES INC. / Nasdaq Stock Markets Inc. / Zurich (UBS Investment Bank) UBS AG / UBS AG / Initial Underlying Level (indicative) Basilea Pharmaceutica AG / Standard & Poor / Vertex Pharmaceuticals Incorporated / Moody's / General Information Issuer Issuer Rating UBS AG / SIX SIS AG / Indicative Terms Selling Restrictions Any Products / Pricing Date ("Pricing") First SIX Trading / S&P / Bloomberg / Fitch / /

Continent

Europe / /

Country

Switzerland / Norway / Austria / United States / Iceland / Liechtenstein / United Kingdom / Singapore / /

Currency

CHF / EUR / /

/

Event

Credit Rating / /

IndustryTerm

investment banking / derivative products / deposit insurance / /

Organization

Financial Conduct Authority / Prudential Regulation Authority / Swiss Bankers Association / Jersey Financial Services Commission / Financial Supervisory Authority / SFA / Swiss Financial Market Supervisory Authority / Monetary Authority of Singapore / European Union / /

/

Position

advisor / advisors / Lead Manager / trustee / General / financial and accounting advisors / Investors General / Expiration Value Official / financial adviser / Manager Calculation Agent Paying Agent / dealer / Private / /

Product

London Branch A2 Moody / /

URL

www.ubs.com/keyinvest / www.ubs.com / /

SocialTag